Answer:
The statement is FALSE.
Explanation:
In genetics, expressivity refers to the amount of variation in a non binary phenotype across individuals, who are carrying a specific genotype. Scientists believed that variable expressivity is controlled by different factors such as environment, genetics and lifestyle choice. An example of expressivity is a series of blue eye color that has different shades of blue. Thus, expressivity is not about balanced genetic output but varied genetic expression.
The hydrogen bonding of nucleotides into a new DNA molecule is facilitated by enzymes. Hydrogen bonding is the electromagnetic attraction between polar molecules in which hydrogen is bound to a larger atom, such as oxygen or nitrogen. The nucleotides in a base pair are complementary which means their shape allows them to bond together with hydrogen bonds. The A-T pairs forms two hydrogen bonds while the C-G pair forms three. The enzymes called DNA polymerases join the nucleotides by way of phosphodiester bonds.
Histone deacetylase is responsible for removing the acetyl group from the histone 3 lysine 9 residue. Remember that deacetylation is one step in converting euchromatin to heterochromatin. Because euchromatin is transcriptionally active (transcriptional machinery is able to reach gene of interest), and blocking histone deacetylase activity would result in an the DNA remaining as euchromatin, we would expect to see an increase in transcriptional activity.
So there’s your answer: An increase in transcriptional activity.
<span>There are three phases of clnic study and one post approval phase required by the Food and Drug Administration (FDA) for a New Drug Application (NDA). Phase IV which is a common stipulation by the FDA includes continual evaluation of the drug after approval has been granted.</span><span />
In meiosis, a diploid parent cell divides to form haploid daughter cells.
